CHICAGO, July 21, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting, sorting and analyzing clinical and molecular data, and Rush University Medical Center (Rush) announce their second collaboration aimed at accelerating research and treatment options for patients battling cancer.
Tempus will help Rush expand and operationalize its research focused biorepository, allowing the hospital to retain and access tissue samples from across the institution that can be used by investigators at Rush to better understand, and eventually treat cancer. In addition, Tempus will collaborate with Rush to develop 3D organoids, and other in-vitro and in-vivo models, which will allow Rush researchers to test how patients may respond to specific treatments; a necessary step toward more personalized cancer care.
“We are pleased to build on our relationship with Rush and to support their efforts to deliver treatments tailored to their patients,” said Eric Lefkofsky, Co-founder and CEO at Tempus. “Whether sequencing and analyzing patient data or building advanced patient derived biological models that can help determine patient response to treatment, we are committed to allowing top hospitals and researchers to access our technology platform in their battle against cancer.”
“Rush is committed to advancing research initiatives that rapidly translate knowledge to practice and usher in the era of personalized medicine,” said Dr. Ranga Krishnan, Dean of Rush Medical College and Senior Vice President at Rush. “The collaboration we are announcing today should allow us over a very short period of time to collect thousands of bio-specimens that will be used to fuel decades of groundbreaking research.”
Tempus currently provides molecular sequencing and analysis for patients being treated for cancer at Rush, along with dozens of other top academic medical centers throughout the country.
About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.
About Rush University Medical Center:
Rush is an academic health system whose mission is to improve the health of the patients and the diverse communities it serves with nationally recognized health care, education, research and a commitment to community partnerships. The Rush system comprises Rush University Medical Center, Rush University, Rush Copley Medical Center and Rush Oak Park Hospital, as well as numerous outpatient care facilities. Rush University, with more than 2,500 students, is a health sciences university that comprises Rush Medical College, the College of Nursing, the College of Health Sciences and the Graduate College.